News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
331,109 Results
Type
Article (19854)
Company Profile (128)
Press Release (311127)
Section
Business (105312)
Career Advice (878)
Deals (18528)
Drug Delivery (96)
Drug Development (50725)
Employer Resources (79)
FDA (7672)
Job Trends (7735)
News (185750)
Policy (17321)
Tag
Academia (730)
Alliances (27806)
Alzheimer's disease (602)
Antibody-drug conjugate (ADC) (75)
Approvals (7671)
Artificial intelligence (113)
Bankruptcy (175)
Best Places to Work (5553)
Biosimilars (78)
Breast cancer (97)
Cancer (872)
Cardiovascular disease (83)
Career advice (709)
Cell therapy (130)
Clinical research (42328)
Collaboration (382)
Compensation (126)
COVID-19 (1087)
C-suite (107)
Data (888)
Diabetes (120)
Diagnostics (1796)
Drug pricing (103)
Earnings (38568)
Employer resources (73)
Events (48150)
Executive appointments (364)
FDA (8114)
Funding (256)
Gene therapy (121)
GLP-1 (539)
Government (1820)
Healthcare (5889)
Infectious disease (1154)
Inflammatory bowel disease (78)
Interviews (115)
IPO (7360)
Job creations (2432)
Job search strategy (646)
Layoffs (269)
Legal (4104)
Lung cancer (135)
Manufacturing (164)
Medical device (1955)
Medtech (1958)
Mergers & acquisitions (11349)
Metabolic disorders (414)
Neuroscience (850)
NextGen: Class of 2025 (2356)
Non-profit (905)
Northern California (900)
Obesity (262)
Opinion (185)
Patents (109)
People (33241)
Pharmaceutical (74)
Phase I (13239)
Phase II (17913)
Phase III (14389)
Pipeline (454)
Policy (89)
Postmarket research (1618)
Preclinical (4604)
Radiopharmaceuticals (158)
Rare diseases (209)
Real estate (3169)
Regulatory (12367)
Research institute (816)
Resumes & cover letters (138)
Southern California (844)
Startups (2006)
United States (8407)
Vaccines (242)
Weight loss (215)
Date
Today (6)
Last 7 days (328)
Last 30 days (1378)
Last 365 days (17443)
2025 (2360)
2024 (17668)
2023 (19637)
2022 (25869)
2021 (26641)
2020 (24872)
2019 (20057)
2018 (15587)
2017 (17253)
2016 (16202)
2015 (18801)
2014 (14787)
2013 (12552)
2012 (13482)
2011 (13817)
2010 (12738)
Location
Africa (407)
Asia (24721)
Australia (3188)
California (2091)
Canada (972)
China (249)
Colorado (88)
Connecticut (88)
Europe (51011)
Florida (344)
Illinois (212)
Indiana (151)
Japan (95)
Maryland (310)
Massachusetts (1745)
Minnesota (115)
New Jersey (830)
New York (609)
North Carolina (439)
Northern California (900)
Ohio (74)
Pennsylvania (488)
South America (605)
Southern California (844)
Texas (275)
Washington State (187)
331,109 Results for "amryt pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Former Amryt Pharma Leadership Team join Poolbeg
Poolbeg Pharma, a clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need, announces the appointment of key former executives of Amryt Pharma plc to its leadership team.
November 9, 2023
·
6 min read
Deals
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici
Amryt Pharma Shareholders approve acquisition of Amryt Pharma by Chiesi Farmaceutici.
March 22, 2023
·
6 min read
FDA
Chiesi’s $1.25B Amryt Buy Pays Off with FDA Approval of Filsuvez
Chiesi Global Rare Diseases gained access to the Filsuvez topical gel in January 2023, when it bought Amryt Pharma. Tuesday’s approval comes nearly two years after an initial rejection by the regulator.
December 20, 2023
·
2 min read
·
Tristan Manalac
Government
Trump’s Whiplash Policies Keep Pharmas on Their Toes
As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives find themselves faced with policy questions ranging from the Inflation Reduction Act to RFK Jr.
February 12, 2025
·
4 min read
·
Annalee Armstrong
GLP-1
Lilly, Novo Skew Overall Pharma Trends With Colossal GLP-1 Sales Growth
From revenue to R&D investment, Novo and Lilly and their mega-blockbuster weight loss drugs Zepbound and Wegovy have moved into a new pharma stratosphere, far eclipsing their rivals.
February 12, 2025
·
2 min read
·
Annalee Armstrong
Deals
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc
Chiesi Farmaceutici S.p.A. announced the completion of the acquisition of Amryt Pharma Plc, a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing, and commercializing novel treatments for rare diseases.
April 12, 2023
·
3 min read
Deals
Chiesi Farmaceutici S.p.A. to Acquire Amryt Pharma Plc
Chiesi Farmaceutici S.p.A. and Amryt Pharma Plc announced that the companies have entered into a definitive agreement under which Chiesi will acquire Amryt.
January 8, 2023
·
12 min read
China
Big Pharma Rushes to China for Deal Prospecting Despite Regulatory Uncertainty
China is adapting its Life Sciences policy to bolster innovation and data transparency. Big Pharma is taking note.
January 7, 2025
·
6 min read
·
Annalee Armstrong
NextGen
After 10 Years of Hard Work, COUR Treads Into Pharma’s Myasthenia Gravis Territory
COUR Pharmaceuticals has been around a while, but not until last year did the company solidify behind its ultimate mission with a series A raise.
February 18, 2025
·
2 min read
·
Annalee Armstrong
Editorial
Pharma’s Q3 Was a Rollercoaster Ride. Let’s Do It Again Next Quarter
Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.
November 15, 2024
·
3 min read
·
Annalee Armstrong
1 of 33,111
Next
